Interpace Biosciences, Inc. (IDXG)

OTCMKTS: IDXG · Delayed Price · USD
3.51
0.05 (1.56%)
May 18, 2022 1:21 PM - Market open
Market Cap14.85M
Revenue (ttm)41.86M
Net Income (ttm)-12.98M
Shares Out4.23M
EPS (ttm)-3.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,001
Open3.50
Previous Close3.46
Day's Range3.50 - 3.52
52-Week Range2.76 - 10.51
Beta1.14
AnalystsSell
Price Target11.22 (+219.3%)
Earnings DateMay 16, 2022

About IDXG

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. ...

IndustryHealth Care Providers & Services
IPO DateMay 20, 1998
CEOJack Stover
Employees147
Stock ExchangeOTCMKTS
Ticker SymbolIDXG
Full Company Profile

Financial Performance

In 2020, IDXG's revenue was $32.40 million, an increase of 33.77% compared to the previous year's $24.22 million. Losses were -$26.45 million, -1.08% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for IDXG stock is "Sell." The 12-month stock price forecast is 11.22, which is an increase of 219.29% from the latest price.

Price Target
$11.22
(219.29% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and...

1 day ago - GlobeNewsWire

Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended...

1 month ago - GlobeNewsWire

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was termina...

3 months ago - GlobeNewsWire

Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, P...

3 months ago - GlobeNewsWire

Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped R...

4 months ago - GlobeNewsWire

Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering

Proceeds to be used to fund the organic growth and prospective product line acquisitions

4 months ago - GlobeNewsWire

Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equi...

PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $8...

6 months ago - GlobeNewsWire

Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determi...

PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecu...

6 months ago - GlobeNewsWire

Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Bio...

PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecu...

6 months ago - GlobeNewsWire

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7...

7 months ago - GlobeNewsWire

Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates

Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma...

10 months ago - Zacks Investment Research

Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services

Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer a...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 an...

1 year ago - GlobeNewsWire

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally pr...

1 year ago - GlobeNewsWire

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in ...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGe...

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agre...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 20...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

Part of Company's Site Consolidation and Cost Savings Measures

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Acceptance for Trading on the OTCQX

PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announ...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Impending Delisting from Nasdaq

PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February ...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces Path Forward in Letter to Shareholders

PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders:

1 year ago - GlobeNewsWire

Interpace Biosciences Announces CFO Leadership Transition

PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has app...

1 year ago - GlobeNewsWire

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, an...

1 year ago - GlobeNewsWire